MX2021010674A - Compuestos triciclicos condensados utiles como agentes anticancerigenos. - Google Patents
Compuestos triciclicos condensados utiles como agentes anticancerigenos.Info
- Publication number
- MX2021010674A MX2021010674A MX2021010674A MX2021010674A MX2021010674A MX 2021010674 A MX2021010674 A MX 2021010674A MX 2021010674 A MX2021010674 A MX 2021010674A MX 2021010674 A MX2021010674 A MX 2021010674A MX 2021010674 A MX2021010674 A MX 2021010674A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds useful
- anticancer agents
- tricyclic compounds
- fused tricyclic
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
La memoria descriptiva se refiere a compuestos de Fórmula (A) (ver Fórmula) y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios utilizados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962813885P | 2019-03-05 | 2019-03-05 | |
US201962951146P | 2019-12-20 | 2019-12-20 | |
PCT/EP2020/055551 WO2020178282A1 (en) | 2019-03-05 | 2020-03-03 | Fused tricyclic compounds useful as anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010674A true MX2021010674A (es) | 2021-09-28 |
Family
ID=69740367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010674A MX2021010674A (es) | 2019-03-05 | 2020-03-03 | Compuestos triciclicos condensados utiles como agentes anticancerigenos. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20220204527A1 (es) |
EP (1) | EP3935060B1 (es) |
JP (1) | JP7453989B2 (es) |
KR (1) | KR20210135539A (es) |
CN (1) | CN113508118A (es) |
AU (1) | AU2020231045B2 (es) |
BR (1) | BR112021017408A2 (es) |
CA (1) | CA3131156A1 (es) |
CL (1) | CL2021002296A1 (es) |
CO (1) | CO2021012381A2 (es) |
CR (1) | CR20210504A (es) |
DO (1) | DOP2021000183A (es) |
EC (1) | ECSP21073246A (es) |
IL (1) | IL285761A (es) |
JO (1) | JOP20210241A1 (es) |
MA (1) | MA55198A (es) |
MX (1) | MX2021010674A (es) |
PE (1) | PE20220140A1 (es) |
SG (1) | SG11202109451TA (es) |
TW (1) | TW202100532A (es) |
UY (1) | UY38602A (es) |
WO (1) | WO2020178282A1 (es) |
ZA (1) | ZA202106192B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
JP7340100B2 (ja) | 2019-10-28 | 2023-09-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Kras g12c変異型の小分子阻害薬 |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
JOP20220142A1 (ar) * | 2019-12-11 | 2023-01-30 | Lilly Co Eli | مثبطات kras g12c |
KR20220130126A (ko) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | Sos1 억제제 |
TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物,其製法與醫藥上的用途 |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
CN114539286B (zh) * | 2020-11-24 | 2024-02-02 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
TW202235082A (zh) | 2020-12-04 | 2022-09-16 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
AR125304A1 (es) * | 2021-04-08 | 2023-07-05 | Genentech Inc | Compuestos de oxazepina acíclicos y usos de los mismos |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
TW202325298A (zh) * | 2021-11-01 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮的四環化合物、其製備方法及其在醫藥上的應用 |
WO2023126822A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008007661A1 (fr) | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique tricycique et son utilisation |
NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
EP3621968A1 (en) * | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2020
- 2020-03-03 JO JOP/2021/0241A patent/JOP20210241A1/ar unknown
- 2020-03-03 PE PE2021001444A patent/PE20220140A1/es unknown
- 2020-03-03 CR CR20210504A patent/CR20210504A/es unknown
- 2020-03-03 MA MA055198A patent/MA55198A/fr unknown
- 2020-03-03 CN CN202080018236.1A patent/CN113508118A/zh active Pending
- 2020-03-03 BR BR112021017408A patent/BR112021017408A2/pt unknown
- 2020-03-03 SG SG11202109451TA patent/SG11202109451TA/en unknown
- 2020-03-03 CA CA3131156A patent/CA3131156A1/en active Pending
- 2020-03-03 KR KR1020217031298A patent/KR20210135539A/ko active Search and Examination
- 2020-03-03 MX MX2021010674A patent/MX2021010674A/es unknown
- 2020-03-03 JP JP2021552640A patent/JP7453989B2/ja active Active
- 2020-03-03 AU AU2020231045A patent/AU2020231045B2/en active Active
- 2020-03-03 US US17/436,137 patent/US20220204527A1/en active Pending
- 2020-03-03 WO PCT/EP2020/055551 patent/WO2020178282A1/en unknown
- 2020-03-03 EP EP20708488.0A patent/EP3935060B1/en active Active
- 2020-03-05 UY UY0001038602A patent/UY38602A/es unknown
- 2020-03-05 TW TW109107275A patent/TW202100532A/zh unknown
-
2021
- 2021-08-22 IL IL285761A patent/IL285761A/en unknown
- 2021-08-26 ZA ZA2021/06192A patent/ZA202106192B/en unknown
- 2021-09-01 DO DO2021000183A patent/DOP2021000183A/es unknown
- 2021-09-02 CL CL2021002296A patent/CL2021002296A1/es unknown
- 2021-09-22 CO CONC2021/0012381A patent/CO2021012381A2/es unknown
- 2021-10-01 EC ECSENADI202173246A patent/ECSP21073246A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202109451TA (en) | 2021-09-29 |
BR112021017408A2 (pt) | 2022-01-18 |
US20220204527A1 (en) | 2022-06-30 |
AU2020231045A1 (en) | 2021-10-28 |
CN113508118A (zh) | 2021-10-15 |
EP3935060C0 (en) | 2023-11-15 |
CR20210504A (es) | 2022-02-08 |
UY38602A (es) | 2020-09-30 |
EP3935060A1 (en) | 2022-01-12 |
WO2020178282A1 (en) | 2020-09-10 |
CL2021002296A1 (es) | 2022-04-29 |
IL285761A (en) | 2021-10-31 |
PE20220140A1 (es) | 2022-01-27 |
AU2020231045B2 (en) | 2023-03-16 |
CO2021012381A2 (es) | 2021-10-20 |
JOP20210241A1 (ar) | 2023-01-30 |
CA3131156A1 (en) | 2020-09-10 |
ZA202106192B (en) | 2022-08-31 |
TW202100532A (zh) | 2021-01-01 |
KR20210135539A (ko) | 2021-11-15 |
MA55198A (fr) | 2022-01-12 |
JP2022523981A (ja) | 2022-04-27 |
ECSP21073246A (es) | 2021-11-30 |
JP7453989B2 (ja) | 2024-03-21 |
EP3935060B1 (en) | 2023-11-15 |
DOP2021000183A (es) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010674A (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos. | |
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
PH12019501724A1 (en) | Estrogen receptor modulators | |
MX2020009062A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos. | |
MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
TW201613864A (en) | Novel compounds | |
MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
MX2020007443A (es) | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. | |
MX2019011265A (es) | Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
AU2022343903A1 (en) | Spirocyclic compounds | |
PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
EA201891027A1 (ru) | Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение | |
MX2021015727A (es) | Derivados de piridin-3-ilo. | |
MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. | |
EA202092600A1 (ru) | Тетрациклические гетероарильные соединения | |
EA201991734A1 (ru) | Модуляторы рецептора эстрогена |